Results 41 to 50 of about 166,676 (142)
T LYMPHOCYTE SUBSETS STUDIED IN A PATIENT WITH TWO ASSOCIATED HEMATOLOGIC NEOPLASIAS – CHRONIC LYMPHOCYTIC LEUKEMIA B AND CHRONIC MYELOID LEUKEMIA [PDF]
Romanian Journal of Medical Practice, 2019 Quantification of various cellular subpopulations facilitates the monitoring of hematological diseases, including chronic lymphocytic leukemia. Variations in the proportions of regulatory T cells in peripheral blood have been described in patients with
Georgiana Ene +3 more
doaj +1 more source
Frontiers in OncologyIntroductionChronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) with ring sideroblasts (RS) or SF3B1 mutation (MDS-RS/SF3B1) differ in many clinical features, but share others, such as anemia.
Blanca Xicoy +20 more
doaj +1 more source
Haematologica, 2009 Background Biphenotypic acute leukemia is a rare disorder that is difficult to diagnose. It displays features of both myeloid and lymphoid lineage. There is still a lack of studies in biphenotypic acute leukemia in a Chinese population. We present here a
Xiao-Qian Xu +9 more
doaj +1 more source
Journal of Medical Case Reports, 2011 Introduction In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions.
Scheid Christoph +5 more
doaj +1 more source
Immunophenotypes of Acute Myeloid Leukemia From Flow Cytometry Data Using Templates [PDF]
arXiv, 2014 Motivation: We investigate whether a template-based classification pipeline could be used to identify immunophenotypes in (and thereby classify) a heterogeneous disease with many subtypes. The disease we consider here is Acute Myeloid Leukemia, which is heterogeneous at the morphologic, cytogenetic and molecular levels, with several known subtypes. The
arxiv
Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]
, 2016 Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan ...
arxiv +1 more source
Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article
مجلة كلية الطبBackground: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram +2 more
doaj +1 more source
Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity
Haematologica, 2008 Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell ...
Désirée Bonci +8 more
doaj +1 more source
IRE1 alpha may be causing abnormal loss of p53 at post transcriptional level in chronic myeloid leukemia [PDF]
arXiv, 2017 Current treatment strategy for chronic myeloid leukemia (CML) mainly includes inhibition of tyrosine kinase activity, which has dramatically improved the prognosis of the disease but without cure. In addition some patients may become drug resistant. Thus there is still the need for other therapies to avoid resistance and if possible to cure the disease.
arxiv
Haematologica, 2008 Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara +13 more
doaj +1 more source